NCT06855628View on ClinicalTrials.gov

Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
GliomaGBM
Interventions
OTHER

[6,6-²H₂]-Glucose

\[6,6-²H₂\]-Glucose is a stable isotope-labeled glucose used as a metabolic tracer. It is administered orally to assess glucose metabolism using Deuterium Metabolic Imaging (DMI).

Trial Locations (1)

94305

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER